Patent · US Active

Long-acting injectable formulations and crystalline forms of buprenorphine derivatives

US11524965B2 · kind B2 · utility

0Cited by
0References
8Claims
0Family size

Assignee

Inventors

Key dates

Filing dateMay 10, 2019
Grant dateDec 13, 2022
Priority date—
Expiry dateMay 10, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC07B2200/13
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

This disclosure relates to crystalline forms of 3-acyl-buprenorphine derivatives and sustained release injectable pharmaceutical compositions for treatment of opioid dependence, pain or depression, including an aqueous suspension of crystalline 3-acyl-buprenoprhine, or a pharmaceutically acceptable salt thereof, wherein the composition does not include an organic solvent, a polylactide polymer, a polyglycolide polymer, or a copolymer of polylactide and polyglycolide. This disclosure also includes 3-acyl-buprenoprhine or a pharmaceutically acceptable salt thereof prepared in a controlled release matrix, including poly(lactide-co-glycolide), sucrose acetoisobutyrate, lecithin, diolein and a combination of two or more thereof.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.